Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Trial Profile

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
    • 02 Dec 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrial.gov record.
    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top